白内障术前房颤人群综合路径管理现状横断面调查

doi:10.6040/j.issn.1673-3770.0.2022.186

摘要/Abstract

摘要： 目的调查白内障术前房颤人群房颤综合路径管理及卒中认知现状,分析危险因素,优化及推动综合路径管理,预防和降低卒中风险。方法选取2021年6月至2022年3月眼科白内障术前心电图检查诊断为房颤的人群。对白内障术前房颤人群发放自制房颤综合路径管理及卒中认知的调查问卷,CHA2DS2-VASc评分,应用SPSS 22.0统计软件进行统计学分析。结果发放自制房颤综合路径管理及卒中认知调查问卷133份,收回133份,有效问卷133份,有效率100%。被调查的白内障术前房颤人群年龄60~95岁,平均年龄(76.83±7.452)岁,房颤人群患病占比为1.44%,房颤患者随年龄增长而增加,男性多于女性。白内障术前房颤人群综合路径管理知晓率及卒中认知率为36.09%,遵循综合路径管理的患者12.03%。抗凝抗血小板治疗率为36.09%,节律控制治疗率为64.66%,卒中率11.28 %。白内障术前房颤人群中61.65%的患者有伴随疾病,这其中24.06%的患者同时伴有2种及以上的伴随疾病。133例房颤患者中有66.17%的患者伴随疾病控制不满意,59.40%的患者存在不健康生活方式,54.88%的患者有不良嗜好。CHA2DS2-VASc评分中高风险患者占73.68%。结论白内障术前房颤人群高龄、伴随疾病高血压、糖尿病以及既往有卒中史,是导致房颤人群卒中风险升高的主要危险因素。对房颤综合路径管理认知度差,卒中知识匮乏认知率低,发现房颤后早期抗凝治疗率低,伴随疾病多且控制不满意,不健康生活方式,不良嗜好等因素是房颤人群卒中风险的潜在危险因素。既往有卒中史未遵循综合路径管理的白内障房颤患者是再卒中高风险人群。应加强白内障术前房颤人群房颤认知的健康教育,指导优化并推动综合路径管理策略。

关键词: 白内障手术, 房颤人群, 综合路径管理, 现状, 危险因素分析

Abstract: Objective To investigate the status of comprehensive pathway management of atrial fibrillation and stroke cognition in a pre-cataract atrial fibrillation population, analyze the associated risk factors, optimize and promote comprehensive pathway management, and prevent and reduce the risk of stroke. Methods From June 2021 to March 2022, a self-made questionnaire on the comprehensive pathway management of atrial fibrillation and stroke cognition was provided to patients with atrial fibrillation before cataract surgery. The CHA2DS2-VASc score was used for statistical analysis using the SPSS 22.0 statistical software. Results We distributed 133 self-made questionnaires on comprehensive pathway management of atrial fibrillation and stroke cognition, and recovered 133 valid responses; the effective rate was 100%. The age of the investigated preoperative atrial fibrillation population was 60-95 years old,(average age: 76.83±7.452 years), and the prevalence rate of atrial fibrillation was 1.44%. The number of patients with atrial fibrillation increased with age, with more men than women. The awareness rate of comprehensive pathway management and the stroke awareness rate in the pre-cataract atrial fibrillation population was 36.09%, and patients who followed the comprehensive pathway management accounted for 12.03%. The anticoagulation/antiplatelet treatment, rhythm control treatment, and stroke rates were 36.09%, 64.66%, and 11.28%, respectively, while 61.65% of the patients with atrial fibrillation before cataract surgery had concomitant diseases, and 24.06% had two or more concomitant diseases simultaneously. Among 133 patients with atrial fibrillation, 66.17% had unsatisfactory disease control, 59.40% had unhealthy lifestyles, and 54.88% had bad habits. High-risk patients accounted for 73.68% in the CHA2DS2-VASc score. Conclusion Among elderly individuals who experience atrial fibrillation before cataract surgery, along with poor awareness of comprehensive management of atrial fibrillation, lack of knowledge about stroke, low rate of early anticoagulation treatment after the identification of atrial fibrillation, many concomitant diseases and unsatisfactory control, unhealthy lifestyle and bad habits are major and potential risk factors for stroke. Cataract and atrial fibrillation patients with a history of stroke who do not follow the comprehensive pathway management are at high risk of re-stroke. Health education on atrial fibrillation cognition in pre-cataract patients with atrial fibrillation should be reinforced to guide optimization and promote comprehensive pathway management strategies.

Key words: Cataract surgery, Atrial fibrillation population, Comprehensive pathway management, Current status, Risk factor analysis

中图分类号:

R779.66

李爱军,崔小梅. 白内障术前房颤人群综合路径管理现状横断面调查[J]. 山东大学耳鼻喉眼学报, 2022, 36(6): 38-44.

LI Aijun, CUI Xiaomei. Current status of comprehensive pathway management atrial fibrillation before cataract surgery: a cross-sectional survey[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(6): 38-44.

参考文献

[1] Odutayo A, Wong CX, Hsiao AJ, et al. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis[J]. BMJ, 2016, 354: i4482. doi:10.1136/bmj.i4482.
[2] Lin T, Wissner E, Tilz R, et al. Preserving cognitive function in patients with atrial fibrillation[J]. J Atr Fibrillation, 2014, 7(1): 980. doi:10.4022/jafib.980.
[3] Mendis S. Stroke disability and rehabilitation of stroke: world Health Organization perspective[J]. Int J Stroke, 2013, 8(1): 3-4. doi:10.1111/j.1747-4949.2012.00969.x.
[4] Sepehri Shamloo A, Dagres N, Hindricks G. 2020 ESC guidelines on atrial fibrillation: summary of the most relevant recommendations and innovations[J]. Herz, 2021, 46(1): 28-37. doi:10.1007/s00059-020-05005-y.
[5] 俞娅娅, 李小荣, 余金波, 等. 心房颤动综合管理ABC方案[J]. 中国心脏起搏与心电生理杂志, 2020, 34(1): 7-10. doi:10.13333/j.cnki.cjcpe.2020.01.003. YU Yaya, LI Xiaorong, YU Jinbo, et al. ABC scheme for comprehensive management of atrial fibrillation[J]. Chinese Journal of Cardiac Pacing and Electrophysiology, 2020, 34(1): 7-10. doi:10.13333/j.cnki.cjcpe.2020.01.003.
[6] Proietti M, Romiti GF, Olshansky B, et al. Improved outcomes by integrated care of anticoagulated patients with atrial fibrillation using the simple ABC(atrial fibrillation better care)pathway[J]. Am J Med, 2018, 131(11): 1359-1366.e6. doi:10.1016/j.amjmed.2018.06.012.
[7] Harding BN, Norby FL, Heckbert SR, et al. Longitudinal measures of blood pressure and subclinical atrial arrhythmias: the MESA and the ARIC study[J]. J Am Heart Assoc, 2021, 10(11): e020260. doi:10.1161/JAHA.120.020260.
[8] Sobieraj P, Nilsson PM, Kahan T. Heart failure events in a clinical trial on arterial hypertension: new insights into the SPRINT trial[J]. Hypertension, 2021, 78(5): 1241-1247. doi:10.1161/HYPERTENSIONAHA.121.17360.
[9] 李烽, 李晓燕, 王如兴. 血糖波动对心房颤动发生的影响及其机制研究进展[J]. 中华心律失常学杂志, 2021, 25(3): 236-238. doi:10.3760/cma.j.cn.113859-20201113-00292. LI Feng, LI Xiaoyan, WANG Ruxing. Research progress of glucose fluctuations on the occurrence of atrial fibrillation and its mechanism[J]. Chinese Journal of Cardiac Arrhythmias, 2021, 25(3): 236-238. doi:10.3760/cma.j.cn.113859-20201113-00292.
[10] Soliman EZ, Safford MM, Muntner P, et al. Atrial fibrillation and the risk of myocardial infarction[J]. JAMA Intern Med, 2014, 174(1): 107-114. doi:10.1001/jamainternmed.2013.11912.
[11] 史晓宁, 王晴晴, 白婷婷, 等. 脑卒中高危人群健康行为及影响因素分析[J]. 全科护理, 2014, 12(10): 934-935, 943. doi:10.3969/j.issn.1674-4748.2014.10.043. SHI Xiaoning, WANG Qingqing, BAI Tingting, et al. Analysis of health behaviors and influencing factors of high-risk population with stroke[J]. Chinese General Practice Nursing, 2014, 12(10): 934-935, 943. doi:10.3969/j.issn.1674-4748.2014.10.043.
[12] Morris A, Elder MJ. Warfarin therapy and cataract surgery[J]. Clin Exp Ophthalmol, 2000, 28(6): 419-422. doi:10.1046/j.1442-9071.2000.00350.x.
[13] Katz J, Feldman MA, Bass EB, et al. Risks and benefits of anticoagulant and antiplatelet medication use before cataract surgery[J]. Ophthalmology, 2003, 110(9): 1784-1788. doi:10.1016/S0161-6420(03)00785-1.
[14] Barequet IS, Sachs D, Shenkman B, et al. Risk assessment of simple phacoemulsification in patients on combined anticoagulant and antiplatelet therapy[J]. J Cataract Refract Surg, 2011, 37(8): 1434-1438. doi:10.1016/j.jcrs.2011.02.035.
[15] Kobayashi H. Evaluation of the need to discontinue antiplatelet and anticoagulant medications before cataract surgery[J]. J Cataract Refract Surg, 2010, 36(7): 1115-1119. doi:10.1016/j.jcrs.2010.01.017.
[16] Steffel J, Collins R, Antz M, et al. 2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation[J]. Europace, 2021, 23(10): 1612-1676. doi:10.1093/europace/euab065.
[17] Unverdorben M, von Heymann C, Santamaria A, et al. Elderly patients with atrial fibrillation in routine clinical practice-peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study[J]. BMC Cardiovasc Disord, 2020, 20(1): 504. doi:10.1186/s12872-020-01766-w.
[18] Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J]. Eur Heart J, 2016, 37(38): 2893-2962. doi:10.1093/eurheartj/ehw210.
[19] January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons[J]. Circulation, 2019, 140(2): e125-e151. doi:10.1161/CIR.0000000000000665.
[20] Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J]. Eur Heart J, 2016, 37(38): 2893-2962. doi:10.1093/eurheartj/ehw210.
[21] Jame S, Barnes G. Stroke and thromboembolism prevention in atrial fibrillation[J]. Heart, 2020, 106(1): 10-17. doi:10.1136/heartjnl-2019-314898.
[22] 董艳, 李小荣, 周秀娟, 等. 心房颤动抗凝治疗的指南更新和实践运用[J]. 中国心脏起搏与心电生理杂志, 2019, 33(2): 95-99. doi:10.13333/j.cnki.cjcpe.2019.02.001. DONG Yan, LI Xiaorong, ZHOU Xiujuan, et al. Chinese Journal of Cardiac Pacing and Electrophysiology[J]. Chinese Journal of Cardiac Pacing and Electrophysiology, 2019, 33(2): 95-99. doi:10.13333/j.cnki.cjcpe.2019.02.001.
[23] 张澍, 杨艳敏, 黄从新, 等. 中国心房颤动患者卒中预防规范(2017)[J]. 中华心律失常学杂志, 2018(1): 17-30. doi:10.3760/cma.j.issn.1007-6638.2018.01.006. ZHANG Shu, YANG Yanmin, HUANG Congxin, et al. Guideline of stroke prevention in Chinese patients with atrial fibrillation(2017)[J]. Chinese Journal of Cardiac Arrhythmias, 2018(1): 17-30. doi:10.3760/cma.j.issn.1007-6638.2018.01.006.
[24] Bassand JP, Apenteng PN, Atar D, et al. GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke[J]. Future Cardiol, 2021, 17(1): 19-38. doi:10.2217/fca-2020-0014.
[25] Kim D, Yang PS, You SC, et al. Comparative effectiveness of early rhythm control versus rate control for cardiovascular outcomes in patients with atrial fibrillation[J]. J Am Heart Assoc, 2021, 10(24): e023055. doi:10.1161/JAHA.121.023055.
[26] Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation[J]. N Engl J Med, 2020, 383(14): 1305-1316. doi:10.1056/nejmoa2019422.
[27] Yang E, Marine JE. Reply to the Editor-Clinical phenotypes of AF patients enrolled in RCTs: AFFIRM and EAST-AFNET 4[J]. Heart Rhythm, 2021, 18(10): 1813. doi:10.1016/j.hrthm.2021.05.025.
[28] Perez MV, Mahaffey KW, Hedlin H, et al. Large-scale assessment of a smartwatch to identify atrial fibrillation[J]. N Engl J Med, 2019, 381(20): 1909-1917. doi:10.1056/NEJMoa1901183.
[29] Staerk L, Wang BQ, Preis SR, et al. Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study[J]. BMJ, 2018, 361: k1453. doi:10.1136/bmj.k1453.
[30] Jiang C, Lan DH, Du X, et al. Prevalence of modifiable risk factors and relation to stroke and death in patients with atrial fibrillation: a report from the China atrial fibrillation registry study[J]. J Cardiovasc Electrophysiol, 2019, 30(12): 2759-2766. doi:10.1111/jce.14231.
[31] 张筑欣, 马长生. 心房颤动的综合管理[J]. 中国实用内科杂志, 2020, 40(3): 177-181. doi:10.19538/j.nk2020030101. ZHANG Zhuxin, MA Changsheng. Comprehensive management of atrial fibrillation[J]. Chinese Journal of Practical Internal Medicine, 2020, 40(3): 177-181. doi:10.19538/j.nk2020030101.
[32] Pastori D, Farcomeni A, Pignatelli P, et al. ABC(atrial fibrillation better care)pathway and healthcare costs in atrial fibrillation: the ATHERO-AF study[J]. Am J Med, 2019, 132(7): 856-861. doi:10.1016/j.amjmed.2019.01.003.
[33] Pokorney SD, Piccini JP. Treatment of atrial fibrillation: is it as easy as A-B-C? [J]. Europace, 2021, 23(2): 161-162. doi:10.1093/europace/euaa361.
[34] Abadie BQ, Hansen B, Walker J, et al. An atrial fibrillation transitions of care clinic improves atrial fibrillation quality metrics[J]. JACC Clin Electrophysiol, 2020, 6(1): 45-52. doi:10.1016/j.jacep.2019.09.001.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed